<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p162" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_162{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_162{left:306px;bottom:30px;}
#t3_162{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_162{left:346px;bottom:30px;}
#t5_162{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_162{left:517px;bottom:30px;}
#t7_162{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_162{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_162{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_162{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_162{left:35px;bottom:777px;letter-spacing:0.04px;word-spacing:0.14px;}
#tc_162{left:35px;bottom:754px;letter-spacing:0.02px;word-spacing:0.17px;}
#td_162{left:440px;bottom:761px;}
#te_162{left:485px;bottom:754px;letter-spacing:0.14px;}
#tf_162{left:35px;bottom:731px;letter-spacing:0.15px;word-spacing:0.05px;}
#tg_162{left:35px;bottom:707px;letter-spacing:0.06px;word-spacing:0.13px;}
#th_162{left:35px;bottom:684px;letter-spacing:0.12px;word-spacing:0.07px;}
#ti_162{left:35px;bottom:661px;letter-spacing:0.1px;word-spacing:-0.29px;}
#tj_162{left:35px;bottom:638px;letter-spacing:0.02px;word-spacing:0.16px;}
#tk_162{left:35px;bottom:614px;letter-spacing:0.18px;word-spacing:0.01px;}
#tl_162{left:35px;bottom:577px;letter-spacing:-0.07px;word-spacing:0.49px;}
#tm_162{left:35px;bottom:552px;letter-spacing:0.13px;word-spacing:0.06px;}
#tn_162{left:35px;bottom:529px;letter-spacing:0.05px;word-spacing:0.14px;}
#to_162{left:35px;bottom:507px;letter-spacing:0.08px;word-spacing:0.11px;}
#tp_162{left:35px;bottom:484px;letter-spacing:0.08px;word-spacing:-1.13px;}
#tq_162{left:35px;bottom:460px;letter-spacing:0.13px;word-spacing:-0.65px;}
#tr_162{left:35px;bottom:437px;letter-spacing:0.08px;word-spacing:0.12px;}
#ts_162{left:35px;bottom:414px;letter-spacing:0.15px;word-spacing:0.04px;}
#tt_162{left:35px;bottom:391px;letter-spacing:0.06px;word-spacing:0.12px;}
#tu_162{left:35px;bottom:368px;letter-spacing:0.1px;word-spacing:0.09px;}
#tv_162{left:35px;bottom:344px;letter-spacing:0.21px;word-spacing:-0.02px;}
#tw_162{left:242px;bottom:352px;letter-spacing:-0.01px;}
#tx_162{left:265px;bottom:344px;letter-spacing:0.13px;word-spacing:0.06px;}
#ty_162{left:35px;bottom:321px;letter-spacing:0.08px;word-spacing:0.1px;}
#tz_162{left:35px;bottom:298px;letter-spacing:0.1px;word-spacing:0.09px;}
#t10_162{left:35px;bottom:275px;letter-spacing:0.05px;word-spacing:0.14px;}
#t11_162{left:35px;bottom:234px;letter-spacing:0.11px;word-spacing:0.08px;}
#t12_162{left:35px;bottom:211px;letter-spacing:0.1px;word-spacing:0.09px;}
#t13_162{left:35px;bottom:188px;letter-spacing:0.01px;word-spacing:-0.53px;}
#t14_162{left:35px;bottom:165px;letter-spacing:0.13px;word-spacing:0.05px;}
#t15_162{left:263px;bottom:172px;letter-spacing:-0.01px;}
#t16_162{left:286px;bottom:165px;letter-spacing:0.11px;word-spacing:0.07px;}
#t17_162{left:35px;bottom:141px;letter-spacing:0.12px;word-spacing:-0.75px;}
#t18_162{left:35px;bottom:118px;letter-spacing:0.07px;word-spacing:0.12px;}
#t19_162{left:35px;bottom:78px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1a_162{left:35px;bottom:55px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1b_162{left:618px;bottom:777px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1c_162{left:618px;bottom:754px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1d_162{left:618px;bottom:731px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1e_162{left:807px;bottom:738px;letter-spacing:-0.01px;}
#t1f_162{left:830px;bottom:731px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1g_162{left:618px;bottom:707px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1h_162{left:1071px;bottom:715px;letter-spacing:-0.01px;}
#t1i_162{left:1094px;bottom:707px;letter-spacing:0.01px;word-spacing:0.17px;}
#t1j_162{left:618px;bottom:684px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1k_162{left:618px;bottom:661px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1l_162{left:1107px;bottom:668px;letter-spacing:0.1px;}
#t1m_162{left:618px;bottom:638px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1n_162{left:618px;bottom:614px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1o_162{left:618px;bottom:591px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1p_162{left:618px;bottom:568px;letter-spacing:0.11px;word-spacing:-0.95px;}
#t1q_162{left:974px;bottom:576px;letter-spacing:-0.01px;}
#t1r_162{left:996px;bottom:568px;letter-spacing:-0.03px;word-spacing:-0.4px;}
#t1s_162{left:618px;bottom:545px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t1t_162{left:618px;bottom:506px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1u_162{left:618px;bottom:482px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1v_162{left:618px;bottom:459px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1w_162{left:618px;bottom:436px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1x_162{left:618px;bottom:413px;letter-spacing:0.1px;word-spacing:-0.38px;}
#t1y_162{left:618px;bottom:390px;letter-spacing:0.08px;word-spacing:-1.13px;}
#t1z_162{left:1073px;bottom:390px;letter-spacing:-0.01px;word-spacing:-1.03px;}
#t20_162{left:618px;bottom:366px;letter-spacing:0.29px;}
#t21_162{left:675px;bottom:366px;letter-spacing:-0.31px;}
#t22_162{left:706px;bottom:366px;letter-spacing:0.18px;word-spacing:-1.22px;}
#t23_162{left:918px;bottom:366px;letter-spacing:0.12px;word-spacing:-1.16px;}
#t24_162{left:1060px;bottom:374px;letter-spacing:-0.31px;}
#t25_162{left:1101px;bottom:366px;letter-spacing:0.14px;word-spacing:-1.18px;}
#t26_162{left:618px;bottom:343px;letter-spacing:0.12px;word-spacing:0.06px;}
#t27_162{left:618px;bottom:320px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t28_162{left:618px;bottom:297px;letter-spacing:0.15px;word-spacing:0.04px;}
#t29_162{left:618px;bottom:273px;letter-spacing:0.05px;word-spacing:-1.1px;}
#t2a_162{left:618px;bottom:250px;letter-spacing:-0.01px;}
#t2b_162{left:665px;bottom:258px;letter-spacing:-0.05px;}
#t2c_162{left:836px;bottom:250px;letter-spacing:0.15px;word-spacing:-0.17px;}
#t2d_162{left:618px;bottom:227px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2e_162{left:618px;bottom:204px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2f_162{left:618px;bottom:181px;letter-spacing:0.18px;word-spacing:0.01px;}
#t2g_162{left:994px;bottom:188px;letter-spacing:0.1px;}
#t2h_162{left:1039px;bottom:181px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2i_162{left:618px;bottom:157px;letter-spacing:0.15px;word-spacing:0.03px;}
#t2j_162{left:618px;bottom:134px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2k_162{left:618px;bottom:111px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t2l_162{left:618px;bottom:88px;letter-spacing:0.1px;word-spacing:-0.19px;}
#t2m_162{left:618px;bottom:64px;letter-spacing:0.26px;word-spacing:-0.07px;}
#t2n_162{left:786px;bottom:64px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2o_162{left:930px;bottom:72px;letter-spacing:-0.01px;}
#t2p_162{left:953px;bottom:64px;letter-spacing:0.32px;word-spacing:-0.13px;}
#t2q_162{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_162{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_162{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_162{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_162{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_162{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_162{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_162{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s7_162{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s8_162{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts162" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg162Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg162" style="-webkit-user-select: none;"><object width="1210" height="935" data="162/162.svg" type="image/svg+xml" id="pdf162" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_162" class="t s0_162">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_162" class="t s1_162">© </span>
<span id="t3_162" class="t s0_162">(NCCN </span>
<span id="t4_162" class="t s1_162">© </span>
<span id="t5_162" class="t s0_162">), All rights reserved. NCCN Guidelines </span>
<span id="t6_162" class="t s1_162">® </span>
<span id="t7_162" class="t s0_162">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_162" class="t s2_162">NCCN Guidelines Version 4.2024 </span>
<span id="t9_162" class="t s2_162">Head and Neck Cancers </span>
<span id="ta_162" class="t s3_162">MS-21 </span>
<span id="tb_162" class="t s4_162">that cetuximab and RT was inferior to cisplatin and RT in patients with </span>
<span id="tc_162" class="t s4_162">HPV-positive locally advanced oropharyngeal cancer. </span>
<span id="td_162" class="t s5_162">285-287 </span>
<span id="te_162" class="t s4_162">When </span>
<span id="tf_162" class="t s4_162">concurrent systemic therapy/RT is recommended for treatment of </span>
<span id="tg_162" class="t s4_162">locoregionally advanced HPV-positive oropharyngeal cancer, the panel </span>
<span id="th_162" class="t s4_162">asserts that high-dose cisplatin is the preferred systemic agent, although </span>
<span id="ti_162" class="t s4_162">weekly cisplatin is also an option. An NRG trial is currently in progress for </span>
<span id="tj_162" class="t s4_162">comparing high-dose cisplatin to weekly cisplatin in locally advanced </span>
<span id="tk_162" class="t s4_162">SCCHN (NCT05050162). </span>
<span id="tl_162" class="t s6_162">Induction Chemotherapy </span>
<span id="tm_162" class="t s4_162">The role of induction chemotherapy in the management of locally </span>
<span id="tn_162" class="t s4_162">advanced SCCHN has generated considerable discussion and debate </span>
<span id="to_162" class="t s4_162">within the NCCN Panel. The lack of consensus among NCCN Member </span>
<span id="tp_162" class="t s4_162">Institutions despite the extensive discussion is illustrated by the category 3 </span>
<span id="tq_162" class="t s4_162">recommendation (ie, major disagreement) for induction chemotherapy for </span>
<span id="tr_162" class="t s4_162">the management of locoregionally advanced p16-negative and p16- </span>
<span id="ts_162" class="t s4_162">positive oropharyngeal cancer. However in other sites of disease (glottic </span>
<span id="tt_162" class="t s4_162">and supraglottic larynx and hypopharynx), category 2A and 2B </span>
<span id="tu_162" class="t s4_162">recommendations for induction chemotherapy are based on an update </span>
<span id="tv_162" class="t s4_162">from the RTOG 91-11 trial. </span>
<span id="tw_162" class="t s5_162">288 </span>
<span id="tx_162" class="t s4_162">For selected patients with hypopharyngeal </span>
<span id="ty_162" class="t s4_162">and laryngeal cancers (with less than T4a in extent, for which total </span>
<span id="tz_162" class="t s4_162">laryngectomy is indicated), induction chemotherapy—used as part of a </span>
<span id="t10_162" class="t s4_162">larynx preservation strategy—is listed as a category 2A designation. </span>
<span id="t11_162" class="t s4_162">Panel members feel that induction chemotherapy should only be </span>
<span id="t12_162" class="t s4_162">administered at sites with expertise in these regimens because of </span>
<span id="t13_162" class="t s4_162">challenges associated with appropriate patient selection and management </span>
<span id="t14_162" class="t s4_162">of treatment-related toxicities. </span>
<span id="t15_162" class="t s5_162">289 </span>
<span id="t16_162" class="t s4_162">Residual toxicity from induction </span>
<span id="t17_162" class="t s4_162">chemotherapy may complicate the subsequent delivery of definitive RT or </span>
<span id="t18_162" class="t s4_162">systemic therapy/RT. </span>
<span id="t19_162" class="t s4_162">A summary of the data helps provide perspective on the NCCN Panel’s </span>
<span id="t1a_162" class="t s4_162">recommendations. Most randomized trials comparing induction </span>
<span id="t1b_162" class="t s4_162">chemotherapy followed by RT and/or surgery to locoregional treatment </span>
<span id="t1c_162" class="t s4_162">alone did not show an improvement in OS with the incorporation of </span>
<span id="t1d_162" class="t s4_162">induction chemotherapy. </span>
<span id="t1e_162" class="t s5_162">275 </span>
<span id="t1f_162" class="t s4_162">However, in some studies, a lower rate of </span>
<span id="t1g_162" class="t s4_162">distant metastases was noted with induction chemotherapy. </span>
<span id="t1h_162" class="t s5_162">290 </span>
<span id="t1i_162" class="t s4_162">Also, a </span>
<span id="t1j_162" class="t s4_162">correlation was noted between favorable tumor response to induction </span>
<span id="t1k_162" class="t s4_162">chemotherapy and durable disease control with subsequent RT. </span>
<span id="t1l_162" class="t s5_162">290,291 </span>
<span id="t1m_162" class="t s4_162">Thus, the hypothesis was developed that induction chemotherapy could </span>
<span id="t1n_162" class="t s4_162">facilitate organ preservation, avoid morbid surgery, and improve QOL of </span>
<span id="t1o_162" class="t s4_162">patients although OS was not improved. Because total laryngectomy is </span>
<span id="t1p_162" class="t s4_162">among the procedures most feared by patients, </span>
<span id="t1q_162" class="t s5_162">292 </span>
<span id="t1r_162" class="t s4_162">larynx preservation was </span>
<span id="t1s_162" class="t s4_162">the focus of initial studies of induction chemotherapy. </span>
<span id="t1t_162" class="t s4_162">Two randomized studies—the Veterans Affairs (VA) Laryngeal Cancer </span>
<span id="t1u_162" class="t s4_162">Study Group trial in advanced larynx cancer and the EORTC trial in </span>
<span id="t1v_162" class="t s4_162">advanced hypopharynx cancer—established the role of induction </span>
<span id="t1w_162" class="t s4_162">cisplatin/5-FU followed by definitive RT in responding patients as an </span>
<span id="t1x_162" class="t s4_162">alternative treatment to total laryngectomy and postoperative RT, offering </span>
<span id="t1y_162" class="t s4_162">potential larynx preservation without compromise in OS (see </span><span id="t1z_162" class="t s7_162">Cancer of the </span>
<span id="t20_162" class="t s7_162">Larynx </span><span id="t21_162" class="t s4_162">and </span><span id="t22_162" class="t s7_162">Cancer of the Hypopharynx </span><span id="t23_162" class="t s4_162">in this Discussion). </span>
<span id="t24_162" class="t s5_162">290,291 </span>
<span id="t25_162" class="t s4_162">Yet, even </span>
<span id="t26_162" class="t s4_162">in this setting, the utilization of induction chemotherapy has decreased </span>
<span id="t27_162" class="t s4_162">with time. Randomized trials and related meta-analyses indicated that </span>
<span id="t28_162" class="t s4_162">concurrent systemic therapy/RT (with cisplatin being the best-studied </span>
<span id="t29_162" class="t s4_162">agent) offered superior locoregional tumor control and OS compared to RT </span>
<span id="t2a_162" class="t s4_162">alone, </span>
<span id="t2b_162" class="t s5_162">264,267-269,271,273,274,276,277 </span>
<span id="t2c_162" class="t s4_162">and shorter duration of therapy compared to </span>
<span id="t2d_162" class="t s4_162">induction therapy followed by radiation. Meta-analyses reported that </span>
<span id="t2e_162" class="t s4_162">concurrent systemic therapy/RT was more efficacious than an induction </span>
<span id="t2f_162" class="t s4_162">chemotherapy followed by definitive RT strategy. </span>
<span id="t2g_162" class="t s5_162">275,293 </span>
<span id="t2h_162" class="t s4_162">In the larynx </span>
<span id="t2i_162" class="t s4_162">preservation setting, the Intergroup 91-11 trial compared RT alone, </span>
<span id="t2j_162" class="t s4_162">concurrent cisplatin/RT, and induction cisplatin/5-FU followed by RT; all </span>
<span id="t2k_162" class="t s4_162">arms offered surgery for locally relapsed/refractory disease. The </span>
<span id="t2l_162" class="t s4_162">concurrent cisplatin/RT arm had the highest larynx preservation rate (see </span>
<span id="t2m_162" class="t s7_162">Cancer of the Larynx </span><span id="t2n_162" class="t s4_162">in this Discussion). </span>
<span id="t2o_162" class="t s5_162">294 </span>
<span id="t2p_162" class="t s4_162">Long-term follow-up of the </span>
<span id="t2q_162" class="t s8_162">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
